Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as ... read more

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ('IBS'), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ('IMC-1'), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden. read less